Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Hepatic necrosis and hemorrhage following hyperthermic intraperitoneal chemotherapy with oxaliplatin: A review of two cases.

Bouchereau M, Gervais MK, Sideris L, Loriot MH, Ahern SP, Dubé P.

J Gastrointest Oncol. 2011 Jun;2(2):113-6. doi: 10.3978/j.issn.2078-6891.2011.012. No abstract available.

2.

Pharmacokinetics of heated intraperitoneal oxaliplatin.

Ferron G, Dattez S, Gladieff L, Delord JP, Pierre S, Lafont T, Lochon I, Chatelut E.

Cancer Chemother Pharmacol. 2008 Sep;62(4):679-83. Epub 2007 Dec 15.

PMID:
18084764
3.

Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies.

Pestieau SR, Belliveau JF, Griffin H, Stuart OA, Sugarbaker PH.

J Surg Oncol. 2001 Feb;76(2):106-14.

PMID:
11223836
4.

Which method to deliver hyperthermic intraperitoneal chemotherapy with oxaliplatin? An experimental comparison of open and closed techniques.

Ortega-Deballon P, Facy O, Jambet S, Magnin G, Cotte E, Beltramo JL, Chauffert B, Rat P.

Ann Surg Oncol. 2010 Jul;17(7):1957-63. doi: 10.1245/s10434-010-0937-z. Epub 2010 Feb 9.

5.

High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: an experimental study.

Facy O, Al Samman S, Magnin G, Ghiringhelli F, Ladoire S, Chauffert B, Rat P, Ortega-Deballon P.

Ann Surg. 2012 Dec;256(6):1084-8. doi: 10.1097/SLA.0b013e3182582b38.

PMID:
22634898
6.

Intraperitoneal hyperthermic chemotherapy in ovarian cancer.

Gori J, Castaño R, Toziano M, Häbich D, Staringer J, De Quirós DG, Felci N.

Int J Gynecol Cancer. 2005 Mar-Apr;15(2):233-9.

PMID:
15823105
7.

Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis.

Ceelen WP, Peeters M, Houtmeyers P, Breusegem C, De Somer F, Pattyn P.

Ann Surg Oncol. 2008 Feb;15(2):535-41. Epub 2007 Oct 25.

PMID:
17960463
8.

Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis.

Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ 3rd.

Cancer. 2010 Aug 15;116(16):3756-62. doi: 10.1002/cncr.25116.

9.

Is palliative laparoscopic hyperthermic intraperitoneal chemotherapy effective in patients with malignant hemorrhagic ascites?

de Mestier L, Volet J, Scaglia E, Msika S, Kianmanesh R, Bouché O.

Case Rep Gastroenterol. 2012 Jan;6(1):166-70. doi: 10.1159/000338070. Epub 2012 Apr 3.

11.

Severe electrolyte disturbances after hyperthermic intraperitoneal chemotherapy: oxaliplatin versus mitomycin C.

Rueth NM, Murray SE, Huddleston SJ, Abbott AM, Greeno EW, Kirstein MN, Tuttle TM.

Ann Surg Oncol. 2011 Jan;18(1):174-80. doi: 10.1245/s10434-010-1210-1. Epub 2010 Jul 8.

PMID:
20614192
12.

Rationale for hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment or prevention of peritoneal carcinomatosis.

Detroz B, Laurent S, Honoré P, Blaffart F, Limet R, Meurisse M.

Acta Chir Belg. 2004 Aug;104(4):377-83. Review.

PMID:
15469146
13.

The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.

Hompes D, D'Hoore A, Van Cutsem E, Fieuws S, Ceelen W, Peeters M, Van der Speeten K, Bertrand C, Legendre H, Kerger J.

Ann Surg Oncol. 2012 Jul;19(7):2186-94. doi: 10.1245/s10434-012-2264-z. Epub 2012 Mar 7.

PMID:
22395983
14.

[Cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion for peritoneal carcinomatosis caused by recurrent inflammatory myofibroblastic sarcoma: a case report and review of the literature].

Mátrai Z, Péley G, Kovács T, Rényi VF, Szívós E, Szabó E, Vereczkey I, Török K, Köves I.

Orv Hetil. 2006 Jan 29;147(4):147-58. Review. Hungarian.

PMID:
16515023
15.

[Preliminary experience with hyperthermic intraperitoneal chemo-perfusion with oxaliplatin for the treatment of peritoneal carcinomatosis due to colorectal carcinoma].

Mura G, Framarini M, Vagliasindi A, Cavaliere D, Tauceri F, Solfrini G, Milandria C, Verdecchia GM.

Chir Ital. 2007 Mar-Apr;59(2):217-23. Italian.

PMID:
17500178
16.
17.

A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer.

Zeh HJ 3rd, Brown CK, Holtzman MP, Egorin MJ, Holleran JL, Potter DM, Bartlett DL.

Ann Surg Oncol. 2009 Feb;16(2):385-94. doi: 10.1245/s10434-008-0179-5. Epub 2008 Nov 25.

PMID:
19034580
18.

Evaluation of quality of life of patients submitted to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis of gastrointestinal and ovarian origin and identification of factors influencing outcome.

Macrì A, Maugeri I, Trimarchi G, Caminiti R, Saffioti MC, Incardona S, Sinardi A, Irato S, Altavilla G, Adamo V, Versaci A, Famulari C.

In Vivo. 2009 Jan-Feb;23(1):147-50.

19.

Hyperthermic intraperitoneal perfusion chemotherapy--views on the observed variability in oxaliplatin pharmacokinetics.

Srinivas NR.

Eur J Clin Pharmacol. 2009 Mar;65(3):321-2. doi: 10.1007/s00228-008-0585-4. Epub 2008 Nov 15. No abstract available.

PMID:
19011850
20.

Feasibility of peritonectomy associated with intraperitoneal hyperthermic perfusion in patients with Pseudomyxoma peritonei.

Deraco M, Gronchi A, Mazzaferro V, Inglese MG, Pennacchioli E, Kusamura S, Rizzi M, Anselmi RA Jr, Vaglini M.

Tumori. 2002 Sep-Oct;88(5):370-5.

PMID:
12487553

Supplemental Content

Support Center